Theralase Technologies Inc. (TLT : TSX-V)
Common Stock
Follow TLT
TLT
Theralase Technologies Inc.
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-2.56%
1 Month
+8.57%
YTD
+5.56%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$58.99M
52W High
$0.41
52W Low
$0.14
P/E Ratio
-
50 Day MA
$0.19
200 Day MA
$0.25
Beta
0.56
Dividend Yield
-
WA Score
How TLT stacks up against 947 Canadian stocks
20
out of 99
- Value32
Not profitable over the last 12 months.
- Quality7
Return on equity −93.4%.
- Momentum47
5.6% this year, below its 200-day average, 17% of the way up its 52-week range.
- Analystsn/a
No analyst target on file.
- Insidersn/a
Not covered by our SEDI insider data yet.
Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks
Performance history
TLT returns since 2023
Theralase Technologies Inc. has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −60.5% (Oct 2024 to Dec 2025).
1 year / yr
−12.2%
3 years / yr
0.0%
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*−5.3%
- 2024+47.2%
- 2025−35.8%
- 2026*+5.9%
* Partial year (first year of data, or year to date).
$10,000 invested in TLT
- 1 year ago$8,780
- 2023 (start of our data)$9,474
- Best year
- 2024: +47.2%
- Worst year
- 2025: −35.8%
- All-time high in our data
- $0 on Apr 24, 2026 · now −53.8%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past TLT? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $0.20 | $0.20 | $0.18 | $0.18 | $0.18 | 35,089 |
| 11/9/2026 | $0.19 | $0.19 | $0.19 | $0.19 | $0.19 | 29,438 |
| 11/6/2026 | $0.20 | $0.20 | $0.18 | $0.19 | $0.19 | 101,753 |
| 11/5/2026 | $0.18 | $0.19 | $0.18 | $0.19 | $0.19 | 145,631 |
| 11/4/2026 | $0.19 | $0.19 | $0.18 | $0.18 | $0.18 | 45,687 |
| 11/3/2026 | $0.20 | $0.20 | $0.18 | $0.18 | $0.18 | 40,902 |
| 11/2/2026 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 1,285 |
| 10/30/2026 | $0.18 | $0.20 | $0.17 | $0.18 | $0.18 | 139,043 |
| 10/29/2026 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 23,500 |
| 10/28/2026 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | 39,890 |
Analyst Price Targets
Based on analyst covering TLT · as of Sep 17, 2026
Wall Street analysts forecast TLT stock price to rise 268.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+268.4% Upside
Current Price
C$0.19
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLT's historical volatility
30-Day Vol
75.5%
Annualized
90-Day Vol
71.5%
Annualized
Trend (90d)
-11.5%
Annualized drift
90d Mean
C$0.17
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.18 | C$0.14 – C$0.23 |
| 60 trading days | C$0.18 | C$0.12 – C$0.25 |
| 90 trading days | C$0.17 | C$0.11 – C$0.27 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Financials
- Revenue (TTM)
- $802,462
- EBITDA
- $-3.65M
- Profit Margin
- 0.00%
- ROE (TTM)
- -93.40%
- EPS (Diluted)
- -0.01
- Book Value
- 0.02
Classification
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Group
- Health Care Equipment & Services
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About TLT
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.